Weaver Consulting Group’s AbbVie ABBV Stock Holding History

Weaver Consulting Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$262K	Sell	1,204 -5	-0.4%	-$1.11K	0.06%	227
2025 Q4	$276K	Buy	1,209 +14	+1%	+$3.19K	0.07%	216
2025 Q3	$277K	Buy	1,195 +33	+3%	+$6.72K	0.07%	207
2025 Q2	$216K	Sell	1,162 -114	-9%	-$21.2K	0.06%	229
2025 Q1	$267K	Sell	1,276 -73	-5%	-$14.2K	0.08%	184
2024 Q4	$240K	Buy	1,349 +74	+6%	+$13.6K	0.07%	187
2024 Q3	$252K	Hold	1,275	–	–	0.08%	187
2024 Q2	$219K	Buy	+1,275	New	+$211K	0.08%	186
2023 Q1	–	Sell	-1,244	Closed	-$201K	–	181
2022 Q4	$201K	Buy	+1,244	New	+$191K	0.1%	168
2022 Q2	–	Sell	-1,396	Closed	-$226K	–	167
2022 Q1	$226K	Sell	1,396 -108	-7%	-$15.7K	0.11%	153
2021 Q4	$204K	Buy	+1,504	New	+$178K	0.1%	162
2020 Q4	–	Sell	-562	Closed	-$49K	–	140
2020 Q3	$49K	Hold	562	–	–	0.03%	269
2020 Q2	$55K	Buy	562 +220	+64%	+$19.4K	0.03%	244
2020 Q1	$26K	Sell	342 -55	-14%	-$4.68K	0.02%	293
2019 Q4	$30K	Buy	397 +74	+23%	+$6.14K	0.02%	305
2019 Q3	$22K	Hold	323	–	–	0.01%	331
2019 Q2	$23K	Hold	323	–	–	0.01%	321
2019 Q1	$25K	Buy	+323	New	+$26.4K	0.01%	666

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weaver Consulting Group's ABBV Position: Q1 2026 in Review

Weaver Consulting Group reduced its AbbVie (ABBV) stake by 0.41% in Q1 2026, selling an estimated $1.11K and leaving 1,204 shares worth $262K. The position accounts for 0.06% of the portfolio, ranked #227.

Weaver Consulting Group first reported a position in ABBV in Q1 2019 and has held it in 18 quarters since. The position peaked at $277K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Weaver Consulting Group held 1,204 shares of AbbVie worth $262K as of Q1 2026.
Weaver Consulting Group sold 5 AbbVie shares in Q1 2026, an estimated $1.11K.
AbbVie made up 0.06% of Weaver Consulting Group's portfolio in Q1 2026, its #227 holding.
Weaver Consulting Group first reported a position in AbbVie in Q1 2019 and has held it in 18 quarters since.
Weaver Consulting Group's AbbVie position peaked at $277K in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Weaver Consulting Group's 13F filing for Q1 2026, filed 15 May 2026.